Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: Effective clearance of its main metabolite by standard hemodialysis treatment

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 3, 2003, Pages 266-270

  Kiani, Alexander ^a   Köhne, Claus Henning ^a   Franz, Thorsten ^a   Passauer, Jens ^a   Haufe, Thorsten ^a   Gross, Peter ^a   Ehninger, Gerhard ^a   Schleyer, Eberhard ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

End stage renal disease; Gemcitabine; Pharmacokinetics

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; ANTIBIOTIC AGENT; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT OBSTRUCTION; BLOOD TOXICITY; CASE REPORT; CHOLANGITIS; CLINICAL FEATURE; CYTOTOXICITY; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TOXICITY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 0344837700     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0574-3     Document Type: Article

References (10)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491
2. Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi N (2001) Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 48:95
3. Golper TA, Marx MA (1998) Drug dosing adjustments during continuous renal replacement therapies. Kidney Int 66:S165
4. Green MR (1996) Gemcitabine safety overview. Semin Oncol 23:32
5. Guchelaar H-J, Richel DJ, van Knapen A (1996) Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 22:15
6. Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G (1977) Model building in pharmacokinetics/part III: simplified rules for the deduction of analytical solutions for linear compartment models. Arzneimittelforschung 27:904
7. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJA, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17:2190
8. Lam YW, Banerji S, Hatfield C, Talbert RL (1997) Principles of drug administration in renal insufficiency. Clin Pharmacokinet 32:30
9. Storniolo AM, Allerheiligen SR, Pearce HL (1997) Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24[2 Suppl 7]:S2
10. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18:2780